No AbstractMechelen, Belgium-based Galapagos NV signed its fifth major pharmaceutical alliance, inking a potential €171.5 million (US$230.4 million)-plus deal with Merck & Co. Inc. to develop drugs aimed at the obesity and diabetes markets.